Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

Launched by UNICANCER ·

Keywords

ClinConnect Summary

This clinical trial is studying two different ways to treat a type of advanced breast cancer called triple-negative breast cancer, which is known to be more difficult to treat. Researchers want to find out if switching back and forth between two medicines—sacituzumab govitecan and trastuzumab deruxtecan—helps patients live longer compared to using just one of these medicines, sacituzumab govitecan, on its own. Both drugs are targeted therapies designed to attack cancer cells more precisely.

The study is open to adults aged 65 to 74 with this type of breast cancer that has spread or is locally advanced, including those whose cancer has a low level of a protein called HER2. People who join the trial will be randomly assigned to either receive the two drugs in an alternating schedule or just sacituzumab govitecan alone. Since the trial is not yet recruiting, those interested should keep an eye out for updates. Participants can expect regular check-ups to monitor their health and how well the treatment is working. This study aims to find better ways to manage this challenging form of breast cancer and improve patients’ outcomes.

Gender

ALL

Eligibility criteria